Skip to main
OSTX
OSTX logo

OSTX Stock Forecast & Price Target

OSTX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OS Therapies Inc. has demonstrated strong clinical efficacy for its treatment OST-HER2, achieving a two-year overall survival rate of 75% in patients with fully resected pulmonary metastatic osteosarcoma, significantly outperforming the historical control rate of 40%. The upcoming biomarker correlation dataset anticipated for November 2025 is poised to enhance the regulatory stance for OST-HER2’s approval process, with regulatory agencies, including the UKMHRA and FDA, signifying their support for the use of historical control data and potential for a conditional approval pathway. Furthermore, the favorable safety and tolerability profile of OST-HER2, along with encouraging indications from multiple regulatory bodies, underscores the therapeutic potential of this treatment in addressing critical needs in oncology for children and young adults.

Bears say

OS Therapies Inc. faces significant financial challenges, including limited revenue generation and the need for substantial capital to fund its ongoing clinical trials, which raises concerns about its ability to sustain operations in the long term. The company’s reliance on external funding and the high costs associated with drug development contribute to its precarious financial position. Additionally, the competitive landscape within the biopharmaceutical industry, particularly for treatments targeting Osteosarcoma and other solid tumors, heightens the risks associated with OS Therapies's market entry and acceptance, further complicating its growth potential.

OSTX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OS Therapies Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OS Therapies Inc (OSTX) Forecast

Analysts have given OSTX a Strong Buy based on their latest research and market trends.

According to 3 analysts, OSTX has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OS Therapies Inc (OSTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.